Carlos del Rio, MD
Infectious Disease · Atlanta, GANPI 1780628982
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (47.9%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 4 manufacturers reported payments, led by Merck at 31.5% of the total. Reporting peaked in 2019 at $7,157 and has fallen 98.0% since, to $140 in 2025.
Across 18 payments — averaging $777.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$4K
- Roche Diagnostics International Ltd$4K
- Gilead$3K
- Sanofi Pasteur Inc.$3K
Across 20 payments — averaging $4715.63 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$94K
- Eli Lilly$113
What the payments were for
- Consulting fees$4,12529%
- Speaking & faculty fees$6,69948%
- Travel & lodging$2,74520%
- Food & beverage$4273%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 5 | $4,406 |
| Roche Diagnostics International Ltd | 1 | $4,144 |
| Gilead | 11 | $2,891 |
| Sanofi Pasteur Inc. | 1 | $2,555 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DELSTRIGO$4,275
- FLUZONE QUADRIVALENT$2,555
How this compares
$13,996 in reported general payments places this provider in the 85th percentile of 260 infectious disease providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other infectious disease in Atlanta
- Zandraetta Tims-CookAtlanta$848K
- Larry AndersonAtlanta$300K
- Quintin RobinsonAtlanta$270K
- James McMillenAtlanta$177K
- Leandro MenaAtlanta$141K
- Colleen KraftAtlanta$103K
- Walter OrensteinAtlanta$78K
- Nadine RouphaelAtlanta$66K
- Kimberly WorkowskiAtlanta$53K
- Bernard BransonAtlanta$36K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.